98%
921
2 minutes
20
Background: Colorectal cancer liver metastasis (CRLM) significantly reduces the survival rate of colorectal cancer patients and increases the complexity of treatment decisions. Analyzing the dynamic interplay of cellular subtypes and phenotypic characteristics in the tumor microenvironment (TME) is essential for developing effective anti-cancer therapies and improving prognosis. Consequently, this research employs bibliometric methods to systematically examine current research focus and emerging developments in the TME associated with CRLM.
Methods: A systematic search of the Web of Science Core Collection was undertaken to retrieve studies released between January 2012 and March 2025. CiteSpace and VOSviewer were mainly used to analyze and visualize country, institution, author, journal, reference, and keyword.
Results: A total of 362 studies were ultimately included in the analysis. China emerged as the leading contributor, followed by the USA, with notable collaborative strength between these nations. Among the institutions, Sun Yat-sen University has the highest publication output. Huang Leaf was the most productive author and Cancer emerged as the most prolific journal. Timeline analysis of keyword clusters demonstrated a persistent research focus on CRLM, liver metastasis, and tumor microenvironment, with immune-related keywords ("immunotherapy," "immune microenvironment," and "PD-L1") gradually emerging since 2020.
Conclusions: Scholars are progressively unraveling the full complexity of the TME in CRLM, and strengthening international cooperation will help accelerate this process. Understanding the dynamic evolution mechanisms of TME following drug treatment and identifying novel therapeutic targets are priorities for future research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334386 | PMC |
http://dx.doi.org/10.1007/s12672-025-03292-7 | DOI Listing |
Cancer Cell
July 2025
Department of Lymphoma and Myeloma, University of Texas (UT) MD Anderson Cancer Center, Houston, TX, USA; Lymphoid Malignancies Program, UT MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mgreen5@mdander
Large B cell lymphomas (LBCL) are clinically and biologically heterogeneous lymphoid malignancies with complex microenvironments that are central to disease etiology. Here, we have employed single-nucleus multiome profiling of 232 tumor and control biopsies to characterize diverse cell types and subsets that are present in LBCL tumors, effectively capturing the lymphoid, myeloid, and non-hematopoietic cell compartments. Cell subsets co-occurred in stereotypical lymphoma microenvironment archetype profiles (LymphoMAPs) defined by; (1) a sparsity of T cells and high frequencies of cancer-associated fibroblasts and tumor-associated macrophages (FMAC); (2) lymph node architectural cell types with naive and memory T cells (LN); or (3) activated macrophages and exhausted CD8 T cells (TEX).
View Article and Find Full Text PDFJ Vis Exp
August 2025
Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa; Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa; Geminii, Inc.
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease.
View Article and Find Full Text PDFJ Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFCancer Immunol Res
September 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields responses in TROP2+ solid tumors but lacks the durability observed with other immunotherapy-based approaches, we developed novel TROP2-targeting chimeric antigen receptor (CAR) T cells as an alternative.
View Article and Find Full Text PDFCancer Immunol Res
September 2025
University of Pennsylvania, Philadelphia, PA, United States.
Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4).
View Article and Find Full Text PDF